RG 7273

Drug Profile

RG 7273

Alternative Names: RG7273

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action ATP binding cassette transporter 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Dyslipidaemias

Most Recent Events

  • 12 Apr 2012 Discontinued - Phase-I for Dyslipidaemias (unspecified route)
  • 03 Nov 2011 RG 7273 is still in phase I trials for Dyslipidaemia
  • 03 Feb 2010 Phase-I clinical trials in Dyslipidaemias (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top